Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P0HI
|
|||
| Former ID |
DCL000483
|
|||
| Drug Name |
AZD8330
|
|||
| Synonyms |
AZD8330; 869357-68-6; AZD-8330; ARRY-424704; ARRY-704; UNII-G4990BOZ66; AZD 8330; 2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; G4990BOZ66; C16H17FIN3O4; 2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide; RWEVIPRMPFNTLO-UHFFFAOYSA-N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Discontinued in Phase 1 | [1], [2] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H17FIN3O4
|
|||
| Canonical SMILES |
CC1=CC(=C(N(C1=O)C)NC2=C(C=C(C=C2)I)F)C(=O)NOCCO
|
|||
| InChI |
1S/C16H17FIN3O4/c1-9-7-11(15(23)20-25-6-5-22)14(21(2)16(9)24)19-13-4-3-10(18)8-12(13)17/h3-4,7-8,19,22H,5-6H2,1-2H3,(H,20,23)
|
|||
| InChIKey |
RWEVIPRMPFNTLO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 869357-68-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
26526760, 29133943, 30508199, 104253466, 124757596, 125164400, 135727827, 136340207, 136367463, 136368067, 136920285, 137032404, 137480889, 144115671, 152258378, 160647215, 162037769, 162202576, 163642776, 163908005, 164045114, 174006482, 174531091, 177749164, 185990462, 198941374, 223704300, 224221833, 226718123, 242585634, 248108609, 251962991, 252110176, 252160640, 252166683, 252214938, 252214939, 252451746, 252543467
|
|||
| ChEBI ID |
CHEBI:91424
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8474). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026144) | |||
| REF 3 | MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.